Ongoing Research Programs Clause Samples

Ongoing Research Programs. As between the Parties, AstraZeneca shall be solely responsible for the Ongoing Research Programs in accordance with accepted pharmaceutical industry norms and ethical practices. It is understood that while AstraZeneca retains the right to complete or wind-down the Ongoing Research Programs in accordance with current commitments under the Ongoing Research Agreements, AstraZeneca shall not expand, extend, or modify (except with respect to wind-down of such Ongoing Research Agreement) the Ongoing Research Programs and/or Ongoing Research Agreements without advance, written consent from Licensee [***] AZD5153. AstraZeneca shall use reasonable efforts to provide Licensee with [***], consistent with Section 2.1.5 where AstraZeneca [***]. Any [***] pursuant to this Section 3.2.3 shall be deemed to be Confidential Information of AstraZeneca. For the avoidance of doubt, [***].
View Source
Ongoing Research Programs. Epix and MKG acknowledge that they are currently engaged in a single Research Program under the Collaboration Agreement which relates to albumin binding for second generation intravascular contrast agents, which Research [*] Omitted portions filed separately with the Securities and Exchange Commission. Program is more fully described in correspondence between Epix and MKG dated [*]. Unless otherwise agreed by Epix and MKG, Epix and MKG agree that there shall be no more than [*] Research Programs being conducted at any time. Unless otherwise agreed by Epix and MKG, should a research program concept be proposed and the Joint Steering Committee recommend that such concept could be added to the Program while [*] Research Programs are being conducted, any such recommended Research Program shall be delayed until [*] the ongoing Research Programs [*] been completed.
View Source

Related to Ongoing Research Programs

  • Research Program The term “

  • Research Project The findings of any research project, which would change the provisions of this Agreement will not be implemented until such changes are negotiated and agreed to by the parties.

  • Research Plan The Parties recognize that the Research Plan describes the collaborative research and development activities they will undertake and that interim research goals set forth in the Research Plan are good faith guidelines. Should events occur that require modification of these goals, then by mutual agreement the Parties can modify them through an amendment, according to Paragraph 13.6.

  • Development Program A. Development activities to be undertaken (Please break activities into subunits with the date of completion of major milestones) B. Estimated total development time

  • Research Term The Research Program will be carried out during the two (2) year period following the Effective Date, unless this Agreement is terminated in accordance with Article 13 (such period, as may be extended pursuant to this Section 3.2, being the “Research Term”). BMS shall have the option to extend the Research Term for three (3) additional one (1) year periods on a year-by-year basis after the initial two (2) year period. At least one hundred eighty (180) days prior to the scheduled expiration of the Research Term (i.e., the applicable anniversary of the Effective Date) BMS will provide Ambrx with a nonbinding, good faith indication of whether or not BMS intends to extend the Research Term. In order to exercise its option to extend the Research Term, BMS must provide Ambrx a written notice exercising BMS’ option to extend the Research Term at least ninety (90) days prior to the scheduled expiration of the Research Term (i.e., the applicable anniversary of the Effective Date). If BMS does not provide such written notice, the Research Term will end when scheduled (i.e., on the applicable anniversary of the Effective Date). For each extension of the Research Term, subject to Section 3.4, the JRC will prepare an update to the Research Plan which will include an updated Budget for the BMS-funded Ambrx FTEs to perform the work required under such Research Plan and the projected Third Party Costs.